Evidence map›Paper›PMID 39950609›Full record

SynthesisActa neuropsychiatrica2025

Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.

Hezekiah C T Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M Teopiz, Angela T H Kwan, Hartej Gill, Sebastian Badulescu, Kyle Valentino, Joshua D Rosenblat and 2 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Acta neuropsychiatrica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Review
  9. Observational
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hezekiah C T AuBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.ORCID https://orcid.org/0009-0002-8786-1550
Yang Jing ZhengBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.ORCID https://orcid.org/0009-0001-3238-696X
Gia Han LeBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Sabrina WongBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Kayla M TeopizBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Angela T H KwanBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Hartej GillMood Disorder Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
Sebastian BadulescuBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Kyle ValentinoBrain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Joshua D RosenblatMood Disorder Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
Rodrigo B MansurMood Disorder Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
Roger S McIntyreDepartment of Psychiatry, University of Toronto, Toronto, Canada.ORCID https://orcid.org/0000-0003-4733-2523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveGlucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) administration has been associated with neuroproliferative effects and modulatory effects in neuronal pathways. Herein, we conducted a comprehensive synthesis of the effects of GLP-1 and GLP-1 RAs on neurogenesis.

methodsWe examined studies that investigate changes in neurogenesis mediated by GLP-1 and GLP-1 RA administration in both human and animal populations. Relevant articles were retrieved through OVID (MedLine, Embase, AMED, PsychINFO, JBI EBP Database), PubMed, and Web of Science from database inception to July 2nd. Primary studies investigating the role of GLP-1 and GLP-1 RAs on neurogenesis were included for analysis.

resultsGLP-1 and GLP-1 RAs (i.e. exenatide, geniposide, liraglutide, lixisenatide, and semaglutide), increased neurogenesis within the dentate gyrus, hippocampus, olfactory bulb, and the medial striatum in animal models. Additionally, GLP-1 and GLP-1 RAs were associated with modulating changes in multiple apoptotic pathways and upregulating survival pathways. DISCUSSION: GLP-1 and GLP-1 RAs are positively associated with neurogenesis. This effect may have translational implications insofar as disparate mental disorders that are characterised by neurogenesis defects (e.g. depressive disorders and neurocognitive disorders) may be benefitted by these agents.

Indexed as

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsNeurogenesisAnimalsExenatideGlucagon-Like Peptide-1 ReceptorHumansLiraglutidePeptidesExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsLiraglutidePeptidesExentaideGLP-1 receptor agonistGlucagon-Like PeptideLiraglutideLixisenatideneurogenesisobesitySemaglutideTirzepatide

Identifiers

PMID39950609
PMCPMC13130299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.